Trials conducted between 2001 and 2007 demonstrated statistically significant reductions in body fat, although the larger Phase IIb OPTIONS trial did not replicate these findings at sufficient magnitude for regulatory approval, and formal development was discontinued in 2007
Tough or dense protein sources are particularly poorly tolerated, and many patients naturally gravitate towards softer, more processed foods that tend to be lower in essential micronutrients
At the cellular level, AOD-9604 exerts its primary effects through a complex mechanism involving beta-3 adrenergic receptors located on the surface of adipocytes (fat cells)
Brief temperature excursions during transport from the refrigerator to injection are fine, but the vial should not sit at room temperature for extended periods
Each injection provides a known amount that the body can use right away
The study funder was not involved in the design of the study